Argenx is a hold due to limited catalysts in 2025, a rich valuation and clinical risk around label expansion. Read more about ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and ...

Having established success in cancer, biopharma is now looking to leverage CAR T therapies against a new target, autoimmune ...

Rheumatologists and cardiologists have long co-managed patients out of necessity and without much formal collaboration or ...

Zai Lab Limited's stock surged 105% in a year. Click to explore ZLAB's $2bn revenue goal, key drugs, and strategic ...

Varied approaches to remote patient monitoring are in development to close care gaps between patients and rheumatologists, ...

Cellares’ Cell Shuttle performed all unit operations in an automated manner, including cell isolation, enrichment, gene ...

We recently published a list of 10 Penny Stocks With Huge Upside Potential According To Analysts. In this article, we are ...